

Seres Therapeutics, Inc.  
Form 8-K  
January 31, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 31, 2017**

**SERES THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-37465**  
**(Commission**  
**File Number)**  
**200 Sidney Street**

**27-4326290**  
**(I.R.S. Employer**  
**Identification No.)**

Edgar Filing: Seres Therapeutics, Inc. - Form 8-K

**Cambridge, MA 02139**

**(Address of principal executive offices) (Zip Code)**

**(617) 945-9626**

**(Registrant's telephone number, include area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On January 31, 2017, Seres Therapeutics, Inc. (the Company ) will host an investor conference call and live webcast to present the results of its in-depth analyses of the previously reported SER-109 Phase 2, 8-week clinical study data in patients with multiply recurrent *Clostridium difficile* infection. A copy of the slide presentation from this conference call is attached as Exhibit 99.1 to this Current Report on Form 8-K. The slide presentation will be archived for approximately 30 days in the Investors & Media portion of the Company s website at [www.serestherapeutics.com](http://www.serestherapeutics.com).

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

<b>No.</b>	<b>Exhibit Description</b>
99.1	SER-109 Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SERES THERAPEUTICS, INC.

Date: January 31, 2017

By: /s/ Eric D. Shaff

Name: Eric D. Shaff

Executive Vice President and Chief Financial

Title: Officer

**EXHIBIT INDEX**

**Exhibit**

**No.**

**Exhibit Description**

99.1 SER-109 Phase 2 Study Analysis Slide Deck for Presentation on January 31, 2017